SAN FRANCISCO, CA and TORONTO, ON — (June 1, 2021) – Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has entered into an agreement (the “Debt Forgiveness Agreement”) with the former shareholders of Talent Biotechs Ltd. (the “Talent Shareholders”), under which Claritas will transfer all assets of its program developing cannabidiol for the prevention and treatment of graft versus host disease (the “GVHD Program”) to the Talent Shareholders in exchange for forgiveness of debt and contingent liabilities.
Claritas Announces Results of Annual General and Special Meeting of Shareholders
SAN FRANCISCO, CA and TORONTO, ON — (June 17, 2021) – Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) held its Annual General and Special Meeting of shareholders (the “Meeting”) today. A total of 214,011,801 common shares (representing approximately 30.5% of all issued and outstanding common shares of the Company) were represented at the Meeting. Shareholders of the Company (the “Shareholders”) voted in favor of all items of business put forth at the Meeting. The complete voting results for each item of business at the Meeting are presented below.
Continue reading Claritas Announces Results of Annual General and Special Meeting of Shareholders
Claritas Announces Publication of Peer-Reviewed Article Reporting that R-107 Significantly Improved Multi-Organ Function and Survival in an Ovine (Sheep) Model of Sepsis
Claritas to Initiate Phase 2 Clinical Testing of R-107 in Treatment of COVID-Related Sepsis Following Completion of Phase 1 Study
SAN FRANCISCO, CA and TORONTO, ON — (December 20, 2021) – Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that the journal Scientific Reports, haspublished a peer-reviewed article reporting that R-107, the Company’s nitric oxide-releasing compound, effectively preserved multi-organ function in a sheep model of sepsis. These significantly positive data suggest that R-107 may be a potentially revolutionary new treatment for sepsis, a life-threatening condition, and the most frequent cause of death in intensive care units due to multiple organ failure.
Claritas Announces Letter of Intent to Acquire Worldwide Rights to R-107 for Treatment of Wound Healing, Skin Ulcers and Severe Burns
SAN FRANCISCO, CA and TORONTO, ON — (January 17, 2022) – Claritas Pharmaceuticals, Inc. (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has signed a Letter of Intent dated January 17, 2022 (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the “Salzman Group”), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of skin ulceration and wound healing, including the treatment of severe burns.
Claritas Announces Formation of Nitric Oxide Scientific Advisory Board
SAN FRANCISCO, CA and TORONTO, ON — (March 8, 2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced the formation of a Scientific Advisory Board (“SAB”) that will work closely with Claritas’ management team to develop nitric oxide-based therapeutics to treat diseases and disorders with significant unmet medical need. The SAB will be led by Dr. Garry J. Southan, an internationally renowned expert in the biology, biochemistry, and chemistry of nitric oxide.
Continue reading Claritas Announces Formation of Nitric Oxide Scientific Advisory Board
Claritas Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107
SAN FRANCISCO, CA and TORONTO, ON — (March 12, 2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has completed GLP toxicology studies of R-107 in rodents. Claritas is developing R-107 as a therapy for vaccine-resistant COVID-19, influenza, and other viral diseases.
Continue reading Claritas Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107
Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107
SAN FRANCISCO, CA and TORONTO, ON — (April 1, 2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has completed GLP genotoxicity studies of R-107. Claritas is developing R-107 as a therapy for vaccine-resistant COVID-19, influenza, and other viral diseases.
Claritas Announces Completion of Canine Toxicology Studies
SAN FRANCISCO, CA and TORONTO, ON — (March 17, 2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has completed toxicology studies of R-107 in canines. On March 12, 2021, Claritas announced strongly positive data from toxicology studies in rodents, and today the Company is announcing equally positive data from toxicology studies in dogs.
Continue reading Claritas Announces Completion of Canine Toxicology Studies
Claritas Announces Approval from Australian Ethics Committee to Begin Phase 1 Trial of R-107
SAN FRANCISCO, CA and TORONTO, ON — (April 5, 2022) – Claritas Pharmaceuticals, Inc. (TSX VENTURE EXCHANGE: CLAS and OTC: CLAZF) (the “Company” or “Claritas“) today announced that the Australian Human Research Ethics Committee has approved the Company’s submission for the Phase 1 clinical study of R-107 to be conducted at Scientia Clinical Research in Sydney, Australia. Claritas will now immediately begin enrollment in the study.
Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors
Ronald Erickson and Robin Hutchison to Resign from the Board
SAN FRANCISCO, CA and TORONTO, ON — (March 18, 2021) – Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas“) today announced that Robert Farrell, J.D., the Company’s President and CEO has been appointed Chairman of the Company’s board of directors (the “Board of Directors”), effective immediately.